ArticleJournal of the National Cancer Institute2024
Trends in new and persistent opioid use in older adults with and without cancer.
Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Racial and ethnic differences in opioid fills following cancer-directed surgery among older and younger Medicare beneficiaries.Journal of the National Cancer Institute · 2026Article
- Effects of Hydrocodone Rescheduling on Pain Management Practices Among Older Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2025Article
- Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Cancer · 2025Article
- A national cohort study of long-term opioid prescription and sociodemographic and health care-related risk factors.Communications medicine · 2025Article
- Purposeful Shared Decision-Making in Caring for and with Patients with Chronic Pain Receiving Opioid Therapy.Journal of general internal medicine · 2025Article
- Persistent prescription opioid use and all-cause mortality following the first-year breast cancer survivorship.JNCI cancer spectrum · 2025Article
- LLM-Guided Pain Management: Examining Socio-Demographic Gaps in Cancer vs non-Cancer cases.medRxiv : the preprint server for health sciences · 2025Article
- Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.Cancer medicine · 2025Review
- Increased pain in veterans with cancer-time to re-evaluate opioid prescribing practices?JNCI cancer spectrum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe impact of ongoing efforts to decrease opioid use on patients with cancer remains undefined. Our objective was to determine trends in new and additional opioid use in patients with and without cancer.
methodsThis retrospective cohort study used data from Surveillance, Epidemiology, and End Results program-Medicare for opioid-naive patients with solid tumor malignancies diagnosed from 2012 through 2017 and a random sample of patients without cancer. We identified 238 470 eligible patients with cancer and further focused on 4 clinical strata: patients without cancer, patients with metastatic cancer, patients with nonmetastatic cancer treated with surgery alone ("surgery alone"), and patients with nonmetastatic cancer treated with surgery plus chemotherapy or radiation therapy ("surgery+"). We identified new, early additional, and long-term additional opioid use and calculated the change in predicted probability of these outcomes from 2012 to 2017.
resultsNew opioid use was higher in patients with cancer (46.4%) than in those without (6.9%) (P < .001). From 2012 to 2017, the predicted probability of new opioid use was more stable in the cancer strata (relative declines: 0.1% surgery alone; 2.4% surgery+; 8.8% metastatic cancer), than in the noncancer stratum (20.0%) (P < .001 for each cancer to noncancer comparison). Early additional use declined among surgery patients (‒14.9% and ‒17.5% for surgery alone and surgery+, respectively) but was stable among patients with metastatic disease (‒2.8%, P = .50).
conclusionsOpioid prescribing declined over time at a slower rate in patients with cancer than in patients without cancer. Our study suggests important but tempered effects of the changing opioid climate on patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.